Predicting nifedipine responses in preterm labor: a risk score incorporating ABCG2 polymorphisms and clinical factors.

IF 1.9 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacogenomics Pub Date : 2025-05-01 Epub Date: 2025-08-01 DOI:10.1080/14622416.2025.2541397

Jungsun Kim, Ji Min Han, Jeong Yee, Young Ju Kim, Suk Joo Choi, Hye Sun Gwak

{"title":"Predicting nifedipine responses in preterm labor: a risk score incorporating ABCG2 polymorphisms and clinical factors.","authors":"Jungsun Kim, Ji Min Han, Jeong Yee, Young Ju Kim, Suk Joo Choi, Hye Sun Gwak","doi":"10.1080/14622416.2025.2541397","DOIUrl":null,"url":null,"abstract":"Background: Nifedipine, a substrate of ATP-binding cassette superfamily G member 2 (ABCG2), is a tocolytic agent. This study aimed to construct a scoring system by exploring the association between ABCG2 polymorphisms and the treatment response of nifedipine in pregnant women.Methods: This study was conducted at a tertiary medical center. Eight single-nucleotide polymorphisms from the ABCG2 gene were selected. The adjusted OR (AOR) were calculated using multivariable analysis. A risk scoring system was constructed by dividing the AOR of independent risk factors by the minimum AOR to predict treatment failure.Results: A total of 69 patients were analyzed for treatment failure. Maternal age ≥33 years, contraction interval <4 minutes, and contraction intensity ≥20 mmHg were clinical risk factors associated with treatment failure. Patients with the ABCG2 rs2622604 and rs4148157 experienced an 8.6-fold and 4.3-fold increased risk of treatment failure, respectively. The predicted risks of treatment failure of patients who scored 0, 1-2, 3-4, 5-6, 7-8, and 9 points were 2.8%, 9.1%, 26.0%, 55.4%, 81.4%, and 93.9%, respectively.Conclusion: This novel risk scoring system may aid clinicians in identifying patients less likely to respond to nifedipine, improving individualized care in preterm labor management.","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"237-246"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427512/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2025.2541397","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Nifedipine, a substrate of ATP-binding cassette superfamily G member 2 (ABCG2), is a tocolytic agent. This study aimed to construct a scoring system by exploring the association between ABCG2 polymorphisms and the treatment response of nifedipine in pregnant women.

Methods: This study was conducted at a tertiary medical center. Eight single-nucleotide polymorphisms from the ABCG2 gene were selected. The adjusted OR (AOR) were calculated using multivariable analysis. A risk scoring system was constructed by dividing the AOR of independent risk factors by the minimum AOR to predict treatment failure.

Results: A total of 69 patients were analyzed for treatment failure. Maternal age ≥33 years, contraction interval <4 minutes, and contraction intensity ≥20 mmHg were clinical risk factors associated with treatment failure. Patients with the ABCG2 rs2622604 and rs4148157 experienced an 8.6-fold and 4.3-fold increased risk of treatment failure, respectively. The predicted risks of treatment failure of patients who scored 0, 1-2, 3-4, 5-6, 7-8, and 9 points were 2.8%, 9.1%, 26.0%, 55.4%, 81.4%, and 93.9%, respectively.

Conclusion: This novel risk scoring system may aid clinicians in identifying patients less likely to respond to nifedipine, improving individualized care in preterm labor management.

查看原文本刊更多论文

预测硝苯地平在早产中的反应：ABCG2多态性和临床因素的风险评分。

背景：硝苯地平是atp结合盒超家族G成员2 （ABCG2）的底物，是一种抗早产药物。本研究旨在通过探讨ABCG2多态性与孕妇硝苯地平治疗反应的关系，构建一个评分系统。方法：本研究在某三级医疗中心进行。从ABCG2基因中筛选出8个单核苷酸多态性。采用多变量分析计算调整后的OR （AOR）。通过独立危险因素的AOR除以最小AOR构建风险评分系统，预测治疗失败。结果：共分析69例治疗失败患者。产妇年龄≥33岁、宫缩间隔ABCG2 rs2622604和rs4148157治疗失败的风险分别增加8.6倍和4.3倍。0分、1-2分、3-4分、5-6分、7-8分、9分患者治疗失败的预测风险分别为2.8%、9.1%、26.0%、55.4%、81.4%、93.9%。结论：这种新颖的风险评分系统可以帮助临床医生识别对硝苯地平反应较小的患者，提高早产儿管理的个性化护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacogenomics 医学-药学

CiteScore

3.40

自引率

9.50%

发文量

审稿时长

4-8 weeks

期刊介绍： Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.